A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease
- Conditions
- lcerative Colitis / Crohn's Disease-
- Registration Number
- JPRN-jRCT2031210210
- Lead Sponsor
- Masaki Takeshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Participants from prior studies who have had at least one study drug administration and have not had early termination of study drug.
-Female participants must agree to contraception requirements.
-Participants must not have developed a new condition, including cancer in the originator study.
-Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study.
-Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
-Requires parenteral nutrition delivered by central vein and/or central venous catheter for venous access.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method